Logo-ipp
Submitted: 11 Dec 2022
Accepted: 19 Feb 2023
ePublished: 27 Feb 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Immunopathol Persa. 2024;10(2): e39477.
doi: 10.34172/ipp.2023.39477
  Abstract View: 326
  PDF Download: 73

Original

Investigating the expression of cytokeratin 5/6 in benign and malignant breast lesions

Seyed Abbas Rezaei Naserabad 1 ORCID logo, Shahram Bagheri 1* ORCID logo, Parvin Kheradmand 1 ORCID logo, Seyed Mahmoud Latifi 2 ORCID logo

1 Department of Pathology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz , Iran
2 Instructor of Biostatistics, School of Health, Diabetes Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
*Corresponding Author: Shahram Bagheri, Email: bagheri-sh@ajums.ac.ir

Abstract

Introduction: Breast cancer (BC) is the most common cancer in women, which is the second most common malignancy in terms of mortality and prevalence after lung cancer. BC is a group of very diverse diseases that can be detected at a molecular, histopathological and clinical level.

Objectives: The aim of the present study was to evaluate the expression of CK5/6 and its relationship to some of the factors affecting prognosis, such as tumor grade, lymph node involvement.

Patients and Methods: In this cross-sectional study with descriptive and analytical aspects, 40 malignant and 20 benign tumors were collected in 2020 from the archives of the pathology department of two educational hospitals in the city of Ahvaz. The demographic and clinical characteristics of each specimen, including age, patient, lymphovascular and perineural invasion, lymph node involvement, tumor grade and tumor type were extracted from the patients’ record. Then the expression of CK5/6 intensity staining was examined by immunohistochemistry.

Results: All benign breast lesions had positive expression for CK5/6 and staining intensity between six and nine. In the malignant group, 33 samples showed negative expression of CK5/6 and only seven samples (17.5%) showed positive expression with a low-staining index. A positive expression with a low-staining index. All seven positive specimens were invasive ductal carcinoma (IDC) lesions with staining index 2, 4, and 6. Additionally, none of the ductal carcinoma in situ (DCIS) specimens which immunostained were positive for CK5/6. In the present study, all IDCs with weak expression of CK5/6 were grade III. No statistically significant relationship was observed between perineural and lymphovascular invasion and lymph node involvement with the intensity of CK5/6 expression.

Conclusion: Our study showed that cytokeratin immunohistochemical intensity is able to distinguish benign lesions from malignant IDC and DCIS lesions and accordingly in determining of tumor grade after weak staining in high-grade IDC, which may be due to squamous metaplasia in these tumors; however, more extensive research with a larger sample size are required to assess its effect in lymphovascular and perineural invasion and also lymph node involvement.


Citation: Rezaei Naserabad SA, Bagheri S, Kheradmand P, Latifi SM. Investigating the expression of cytokeratin 5/6 in benign and malignant breast lesions. Immunopathol Persa. 2024;10(2):e39477. DOI:10.34172/ ipp.2023.39477.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 327

Your browser does not support the canvas element.


PDF Download: 73

Your browser does not support the canvas element.